Australia's Chimeric Therapeutics falls on discounted placement
** Chimeric Therapeutics CHM.AX falls 7.7% to A$0.006, lowest since February 26 ** Biotech firm says it intends to raise up to A$3.2 mln ($1.99 mln) at A$0.005, a discount of 28.6% to last close ** Adds funds will used for continued development of co's CDH17 Phase 1/2 clinical trial ** Stock down 14.3% YTD ($1 = A$1.6116) (Reporting by Kumar Tanishk in Bengaluru) ((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial